I am referring to the corp officer in the article who has quit to form a company called AMRYX. In talking with someone from the company, I found out that they will infact take the taste Genomics wiht them and develop this further. It seems to be a wholly owned subs of Aurora.
I was originally afriad that this was an unauthorized spinoff in which one guy decides to leave and the company has to take a defensive promotion position to keep the rest. I do not now think this is the case after investigating it.
Sorry, I found that nobody had posted it yet, so here goes...
******************************
Aurora Biosciences Announces Management Changes
PR Newswire - April 09, 1999 09:15
SAN DIEGO, April 9 /PRNewswire/ -- Aurora Biosciences Corporation (Nasdaq: ABSC) today announced the promotions of John Mendlein, J.D., Ph.D. to
chief knowledge officer and senior vice president, Intellectual Property, from general counsel and vice president, Intellectual Property; Eric Hotaling to vice
president, Engineering and Production from senior director, Engineering Operations; Paul Negulescu, Ph.D. to senior director, Cell Biology from director, Cell
Biology; and Kleanthis Xanthopoulos, Ph.D. to senior director, Molecular Biology and Genomics from director, Molecular Biology and Genomics.
Timothy J. Rink, M.D., Sc.D., chairman, chief executive officer and president of Aurora, said, "These promotions reflect the many contributions of these
individuals to the company's progress, as well as the added responsibilities they have assumed as the company expands its intellectual property and technology
platform, proceeds with the development and production of instrumentation and automation for ultra-high throughput screening, and continues to grow its
screening services and its human cell functional genomics GenomeScreen(TM) program."
The Company also announced that Paul Grayson, senior vice president, Corporate Development, has resigned from Aurora to become the chief executive
officer and president of Ambryx, Inc., a newly-formed biotechnology company focused on the discovery and development of products in the area of taste,
smell and pheromone detection. He will continue to serve Aurora as a consultant in the area of corporate development. "Paul has made important contributions
to the growth and progress of Aurora over the past three years, with a key role in establishing our major corporate collaborations," said Timothy J. Rink. "We
are very appreciative of his accomplishments and wish him well in his exciting new venture."
Aurora designs and develops proprietary drug discovery systems, services and technologies to accelerate and enhance the discovery of new medicines. Aurora
is developing an integrated technology platform comprised of a portfolio of proprietary fluorescent assay technologies and an Ultra-high Throughput Screening
System ("UHTSS")(TM) platform designed to allow assay miniaturization and to overcome many of the limitations associated with the traditional drug
discovery process. The Company believes that the UHTSS(TM) platform will enable Aurora and its collaborators to take advantage of the opportunities
created by recent advances in genomics and combinatorial chemistry that have generated many new therapeutic targets and an abundance of new, small
molecule compounds. Current collaborators include Merck & Co., Inc., Warner-Lambert Company, Bristol-Myers Squibb Co., Eli Lilly and Company, F.
Hoffmann-La Roche Ltd., Pharmacia & Upjohn, Inc., Becton Dickinson & Company, and Cytovia, Inc.
Statements in this press release that are not strictly historical are "forward-looking" statements which involve a high degree of risk and uncertainty. Such
statements are only predictions and the actual events or results may differ materially from those projected in such forward-looking statements. Factors that
could cause or contribute to differences include risks involved with the Company's new and uncertain technologies and growth and development of new
programs, risks associated with the dependence on patents and proprietary rights, the ability to attract additional collaborative partners, dependence on existing
pharmaceutical and biotechnology collaborations, and the development or availability of competing systems. These factors and others are more fully described
in the Company's Annual Report on Form 10-K for the fiscal year ended December 31, 1998, as filed with the Securities and Exchange Commission. For
additional corporate information, visit the Aurora website at aurorabio.com.
SOURCE Aurora Biosciences Corporation
/CONTACT: John Mendlien, Chief Knowledge Officer and Senior VP,
Intellectual Property, 619-404-6639, Fax: 619-404-6714,
mendleinj@aurorabio.com, or Angela Hartley, Director, Corporate Communications
and Investor Relations, 619-404-6767, Fax: 619-404-6714,
hartleya@aurorabio.com, both of Aurora Biosciences Corporation/
/Web site: aurorabio.com
(ABSC) |
